Rationale, design and objectives of two phase III, randomised, placebo-controlled studies of GLPG1690, a novel autotaxin inhibitor, in idiopathic pulmonary fibrosis (ISABELA 1 and 2)

INTRODUCTION: While current standard of care (SOC) for idiopathic pulmonary fibrosis (IPF) slows disease progression, prognosis remains poor. Therefore, an unmet need exists for novel, well-tolerated agents that reduce lung function decline and improve quality of life. Here we report the design of t...

Descripción completa

Detalles Bibliográficos
Autores principales: Maher, Toby M, Kreuter, Michael, Lederer, David J, Brown, Kevin K, Wuyts, Wim, Verbruggen, Nadia, Stutvoet, Simone, Fieuw, Ann, Ford, Paul, Abi-Saab, Walid, Wijsenbeek, Marlies
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Interstitial Lung Disease
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6530501/
https://www.ncbi.nlm.nih.gov/pubmed/31179008
http://dx.doi.org/10.1136/bmjresp-2019-000422

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6530501/
https://www.ncbi.nlm.nih.gov/pubmed/31179008
http://dx.doi.org/10.1136/bmjresp-2019-000422

Ejemplares similares